Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Connexios: Harnessing the Indian cost advantage in network biology

This article was originally published in Scrip

Executive Summary

Imagine if a start-up company could afford to hire enough high-calibre scientists to spend years creating a detailed map of a broad and complex pathology like metabolic disease, incorporating large amounts of cellular and molecular biological data, into which it could plug further swathes of clinical information. Imagine if it was then able to evaluate existing drug R&D against this map, and identify promising areas for potential future drug discovery and development, which it would then proceed to carry out itself. All with the financial backing of an enthusiastic private investor. It seems unlikely, but this is precisely what Connexios Life Sciences has done. Scrip's companies editor Eleanor Malone met CEO Dr Suri Venkatachalam to find out more.

You may also be interested in...



Editor's Note: Join Our Survey To Shape Scrip's Future

We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the format of the content or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

 

What Does 2020 Hold For Biopharma?

Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.

Scrip Asks… What Does 2020 Hold For Biopharma? Part 4: The Patient

From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.

Topics

Related Companies

UsernamePublicRestriction

Register

SC008975

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel